Today NICE (National Institute for Health and Care Excellence) published their revised guidelines on immunosuppressive therapy for kidney transplant in adults, following a number of appeals by various organisations, including Kidney Care UK.
Fiona Loud, Policy Director at Kidney Care UK, says: “We are pleased that the guidance, published today, means that revised recommendations are now in place so patients will still be able to access the full range of therapies to prevent the body rejecting a transplant, if they are unable to tolerate the initial recommended treatments. Thanks to the arguments made by Kidney Care UK, patients and clinical experts, 20% of people who would have been in danger of not being able to have or maintain a transplant will be able to continue with their treatment. We are delighted that NICE has allowed many of our appeal points, which has resulted in their guidance giving clarity and flexibility for adults who have had kidney transplants.”
The organisations whose appeal points were allowed:
- Kidney Care UK – four points in full, one in part – all relating to the lack of clarity in the final appraisal determination regarding second-line treatment
- ESPIRIT– two points in full – all relating to the lack of clarity in the final appraisal determination regarding second-line treatment
- NHS England – three points in part – all relating to the lack of clarity in the final appraisal determination regarding second-line treatment
Read the full guidelines on immunosuppresive therapy for kidney transplant in adults